|Home||» Products||» Hepatitis Medicine||» Daclatasvir 60mg Tablets|
Packing - 1*28 Tablet
Company - Hetro
contain - Daclatasvir
DaclaHep contain Daclatasvir 60mg . DaclaHep is for the treatment of Hepatitis C.
DaclaHep should be taken with doctor prescriptin only.
K M healthcare is trader or supplier of DaclaHep Tablet.
We supply the medicine on the doctor presription or to the medicine license holder only.
Sofosbuvir Is indicated for the treament fo Hepatitis C.
Hepatitis C is a liver disease caused by the hepatitis C virus the virus can cause both acute and chronic hepatitis infection, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness.
The hepatitis C virus is a bloodborne virus and the most common modes of infection are through unsafe injection practices, inadequate sterilization of medical equipment, and the transfusion of unscreened blood and blood products.
Globally, between 130â150 million people globally have chronic hepatitis C infection.
A significant number of those who are chronically infected will develop liver cirrhosis or liver cancer.
There is currently no vaccine for hepatitis C; however research in this area is ongoing.
The hepatitis C virus is a bloodborne virus. It is most commonly transmitted through:
injecting drug use through the sharing of injection equipment;
the reuse or inadequate sterilization of medical equipment, especially syringes and needles in healthcare settings; and
the transfusion of unscreened blood and blood products.
Sofosbuvir should be used in combination with ribavirin or with pegylated interferon and ribavirin
Sofosbuvir is effective for the treatment of HCV in Genotyp 1 ,Genotype 2 ,Genotype 3 , Genotype 4.
Sofosbuvir and ribavirin therapy for 24 weeks can be considered for patients with genotype 1.
MyhepLvir Sofosbuvir + Ledipasvir show the cure rate of 95 to 97 % In Genotype 1 non Cirrhosis Patient. Myhep Lvir or can be used in thr treatment of HIV+HCV Coinfections.
Cure rate means there is no detection of HCV virus in the blood 3 month after treatment is complated.
In Clinical Studies Sofosbuvir and Valpatasvir Cure rates are 99 % In genotype 2 and 95% In Genotype 3 Patient.
In Genotype 1 and GT4 and GT5 MyhepAll show the cure rate of 97 to 100%
K M Healthcare is supplier of MYHEPALL, Myhep Lvir, Myhep , Ribavarin, Sofosbuvri & Daclastavir Combination or Sofosbuvir+ Ledipasvir Combination or Ipclusa Sofosbuvir + Valpatasvir Combnation.
We supply the medicine worldwide . We have client in India, Cambodia, Vietnam , Africa, Russia, China , UK , Europe, Canada , Belarus , Ukraine ,Tazakistan, Iran ,Latin America , Hongkong and many more country .